Close Menu

Liquid Biopsy

News and reporting on cell-free DNA testing.

Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.

The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.

The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.

The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials. 

The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.